研究设计和对Tadalafil治疗COPD-PH中炼相关呼吸障碍的呼吸更容易的理由 (更好的COPD-PH)
Elena DeSanti1, Matthew Jankowich1, Gaurav Choudhary1
1VA Providence Healthcare System Providence USA.
固酶类型-5抑制剂 (PDE5i) 与塔达拉菲尔的治疗可能会改善COPD肺高血压 (COPD-PH) 患者的呼吸障碍和生活质量. 进一步的研究正在进行中,以证实这些益处.
科学领域:
- 肺部医学 肺部医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘息严重影响慢性阻塞性肺病 (COPD) 患者的生活质量和生存率.
- 肺高血压 (PH) 是一个常见的COPD并发症,恶化呼吸困难和死亡率.
- 减少的氧化 (NO) 信号导致COPD-PH,而PDE5抑制剂可以恢复NO信号.
研究的目的:
- 评估PDE5抑制剂 (PDE5i) 塔达拉菲尔对COPD-PH患者呼吸障碍的影响.
- 评估PDE5i治疗是否可以减轻这种患者群体中呼吸障碍的衰弱症状.
主要方法:
- 一个前性的,随机的,双盲的多中心临床试验 (NCT05937854).
- 参与者将接受6个月的最大耐受性达拉菲尔 (40毫克/天) 或安慰剂.
- 呼吸障碍将使用加利福尼亚大学圣地亚哥呼吸短促问卷进行测量.
主要成果:
- 以前的研究表明,塔达拉菲尔没有改善6分钟的步行距离,但在6个月后改善了患者报告的呼吸障碍和HRQL.
- 目前的研究旨在证实这些发现,以呼吸障碍作为主要结局.
结论:
- 在COPD-PH患者中,PDE5i治疗有望减少呼吸障碍.
- 需要进一步的研究来确定PDE5i在COPD-PH管理中的有效性.
更多相关视频
08:44Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
Published on: February 2, 2024
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-I: Introduction
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
